Side-by-side · Research reference

DSIPvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 2Reviewed8/46 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

DSIP

TB-500

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

DSIP

TB-500

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

Once daily, pre-sleep

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

50 mcg pre-sleep

1 mg per injection

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

8–12 weeks per cycle

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

Bacteriostatic water

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

30–60 min pre-sleep

Evening or pre-rest preferred (anecdotal)

Half-life

Short plasma; CNS effects last hours

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

DSIP

TB-500

Injection site reaction

Mild irritation

Mild erythema, transient pain

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

Unknown beyond Phase 2

Pregnancy / OB

Avoid

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

DSIP

TB-500

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Injection site

SQ — abdomen. Rotate sites.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

30–60 min pre-sleep.

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

29–31G insulin syringe.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

DSIP

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair